Ahammune’s current program is on the depigmenting disorder, Vitiligo. The mission of Ahammune Biosciences is to arrest the progress of Vitiligo and to induce re-pigmentation of depigmented patches. Ahammune has filed its first Investigational New Drug (IND) Application with the Drug Controller General of India (DCGI) for approval to conduct human studies with its lead drug candidate for vitiligo. Apart from the treatment for vitiligo, the company is aiming to target multiple dermatological indications with its deep pipeline of IP-based molecules that modulate cellular pathways underlying skin health and immunity. The company has been founded on the basis of finding cost-effective solutions for chronic skin diseases. Earlier, Ahammune established the efficacy and safety of its drugs in preclinical animal studies and is now transitioning into a clinical phase company. In April 2021, the company raised an undisclosed amount in a Pre-Series A round led by Ideaspring Capital and Indian Angel Network.
